Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCZC4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,392
Award facts
- Contract value 100% obligated
- $11,392.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,392.44 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL syringes. The delivery order, issued on December 18, 2025, with an ultimate completion date of January 12, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion governmentwide acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with a substantial portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's performance on this delivery order supports the broader military healthcare mission by providing immunosuppressant therapies essential for patient care across DoD medical facilities. As one of multiple regional prime vendor contractors under the PPV-G GEN V framework, which features a 30-month base period and three 30-month option periods extending through December 31, 2036, DMS Pharmaceutical Group continues to demonstrate its capacity to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCZC4?
SPE2DR26FCZC4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FCZC4 worth?
The government has obligated $11,392 on SPE2DR26FCZC4.
Is contract SPE2DR26FCZC4 an order under another contract?
Yes. SPE2DR26FCZC4 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZC4 competed?
The extent of competition for SPE2DR26FCZC4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award